docetaxel + bicalutamide + goserelin + prednisone

This neoadjuvant chemohormonal therapy (NCHT) regimen, studied at RenJi Hospital, is a combination treatment for locally advanced, high-risk prostate cancer. It consists of the taxane chemotherapy agent docetaxel administered intravenously, paired with a comprehensive androgen deprivation therapy (ADT) blockade using the oral androgen receptor antagonist bicalutamide and the subcutaneous GnRH receptor agonist goserelin. Prednisone is also included to mitigate docetaxel-induced toxicity and suppress adrenal androgen production. The regimen is typically administered for 4 to 6 cycles prior to radical prostatectomy. Clinical trial results from RenJi Hospital demonstrated that this intensive neoadjuvant approach significantly improves 3-year biochemical recurrence-free survival compared to standard neoadjuvant hormonal therapy alone by targeting both rapidly dividing cells and the androgen signaling axis that drives prostate malignancy.

Other names

Neoadjuvant chemohormonal therapyDocetaxel and Hormone Therapy in Locally Advanced Prostate CancerNeoadjuvant chemotherapy combined with hormone therapy